Joshua Scheinker

Cranius LLC is a company based in Maryland that aims to invent and engineer technology to define the future of diagnostics and treatments for patients with chronic brain disease. The American company's flagship device, the Neuropass, is being developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective. Cranius utilizes a novel pump design, refillable reservoir, MRI-lucent components, and wireless charging technology to enable long-term and direct medicine administration. The company was founded in May 2021 as a byproduct of the emerging field known as "neuroplastic and reconstructive surgery," through the vision, insight, and pioneering work of Dr. Chad Gordon. The CEO is Mike Maglin.

Cranius LLC is a company based in Maryland that aims to invent and engineer technology to define the future of diagnostics and treatments for patients with chronic brain disease. The American company's flagship device, the Neuropass, is being developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective. Cranius utilizes a novel pump design, refillable reservoir, MRI-lucent components, and wireless charging technology to enable long-term and direct medicine administration. The company was founded in May 2021 as a byproduct of the emerging field known as "neuroplastic and reconstructive surgery," through the vision, insight, and pioneering work of Dr. Chad Gordon. The CEO is Mike Maglin.

Cranius LLC is a company based in Maryland that aims to invent and engineer technology to define the future of diagnostics and treatments for patients with chronic brain disease. The American company's flagship device, the Neuropass, is being developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective. Cranius utilizes a novel pump design, refillable reservoir, MRI-lucent components, and wireless charging technology to enable long-term and direct medicine administration. The company was founded in May 2021 as a byproduct of the emerging field known as "neuroplastic and reconstructive surgery," through the vision, insight, and pioneering work of Dr. Chad Gordon. The CEO is Mike Maglin.

Cranius LLC is a company based in Maryland that aims to invent and engineer technology to define the future of diagnostics and treatments for patients with chronic brain disease. The American company's flagship device, the Neuropass, is being developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective. Cranius utilizes a novel pump design, refillable reservoir, MRI-lucent components, and wireless charging technology to enable long-term and direct medicine administration. The company was founded in May 2021 as a byproduct of the emerging field known as "neuroplastic and reconstructive surgery," through the vision, insight, and pioneering work of Dr. Chad Gordon. The CEO is Mike Maglin.

Cranius LLC is a company based in Maryland that aims to invent and engineer technology to define the future of diagnostics and treatments for patients with chronic brain disease. The American company's flagship device, the Neuropass, is being developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective. Cranius utilizes a novel pump design, refillable reservoir, MRI-lucent components, and wireless charging technology to enable long-term and direct medicine administration. The company was founded in May 2021 as a byproduct of the emerging field known as "neuroplastic and reconstructive surgery," through the vision, insight, and pioneering work of Dr. Chad Gordon. The CEO is Mike Maglin.